Rossignol P, Zannad F, Massy Z, Azizi M, et al. Spironolactone in patients on chronic haemodialysis at high risk of adverse cardiovascular outcomes (ALCHEMIST): a multicentre, double-blind, randomised, placebo-controlled trial and updated meta-analysis. Lancet 2025;406:705-718.
PMID: 40818851